# Zenas BioPharma, Inc. (ZBIO) FY2026 YTD Q2 P&L / Income Statement

- Company: Zenas BioPharma, Inc. (ZBIO)
- Period: 2026-01-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-13, accession number 0001104659-26-095448
- Page: https://plicit.ai/financials/zbio/fy2026-ytd-q2-income-statement
- Chart image: https://plicit.ai/charts/zbio-fy2026-ytd-q2-income-statement-sankey.png

## Chart details

Income statement for 2026-01-01 through 2026-06-30. Consolidated revenue, costs and expenses.

- **Total revenue**: 1,000,000 US dollars
- **Total operating expenses**: 186,009,000 US dollars
- **Loss from operations**: negative 185,009,000 US dollars
- **Total other income (expense), net**: negative 7,320,000 US dollars
- **Loss before income taxes**: negative 192,329,000 US dollars
- **Income tax provision (benefit)**: 114,000 US dollars
- **Net loss**: negative 192,443,000 US dollars
- **Undisclosed sources**: 1,000,000 US dollars. The filing reports revenue as one line and discloses no sources of it.
- **Total operating expenses**: 186,009,000 US dollars

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.